Zhejiang Hisun Pharmaceutical
600267 · SSE
Public Market Listing
600267SSE
Live quotes, historical charts, and market capitalization for Zhejiang Hisun Pharmaceutical are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
HyzetimibeNo recent activity | Phase 3 | NPC1L1Small molecule | Atherosclerotic Cardiovascular Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $724M | — | — | — | report ↗ |
Zhejiang Hisun Pharmaceutical reported revenue of $724.42M for H1 2025.
Figures only: this period's report disclosed no narrative text
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.5B | $67M | — | — | report ↗ |